ArticleBMC medical imaging2025
SegMambaDP: a long-range sequential modeling mamba network for 3D dose prediction in radiotherapy.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A deep learning-driven automated treatment planning framework for cervical cancer patients treated with volumetric modulated arc therapy.Radiation oncology (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy is a cornerstone of cancer treatment, and its therapeutic efficacy critically depends on the precision of the delivered dose distribution. The current clinical standard for treatment planning involves an inverse optimization process where physicists define clinical objectives and constraints, followed by computationally intensive dose calculations, often using methods like Monte Carlo simulation. While accurate, this iterative process is time-consuming, leading to delays and potential variability in plan quality. Deep learning methods have improved dose-prediction accuracy, but they often struggle to model fine-grained spatial relationships in complex anatomy. This study aims to develop a novel State Space Model (SSM)-based network for accurately predicting 3D radiotherapy dose distributions in head and neck (H&N) and cervical cancer.
methodsWe introduce SegMambaDP, an SSM–based network for 3D dose prediction, and evaluate it on the OpenKBP dataset and an institutional cervical-cancer VMAT cohort. The network employs a cascading architecture that integrates a Tri-orientated Mamba (ToM) module to strengthen long-range dependency modeling of 3D features and a feature-level Uncertainty Estimation (FUE) module to enhance multi-scale feature fusion. Moreover, SegMambaDP incorporates both anatomical structure and beam angle information to boost clinical adaptability. Finally, model performance was assessed by comparison with existing methods using the Dose score, DVH score, and relevant dosimetric indicators using the 2020 AAPM OpenKBP Challenge dataset and our institution’s cervical cancer dataset.
resultOn the OpenKBP dataset, SegMambaDP achieved a Dose score of 2.398 ± 1.028 Gy and a DVH score of 1.254 ± 1.660 Gy. On the cervical cancer dataset, it achieved a Dose score of 2.428 ± 1.028 Gy and a DVH score of 1.274 ± 1.760 Gy. In both datasets, the predicted Conformity Index (CI) and Homogeneity Index (HI) for the Planning Target Volume (PTV) closely matched the true values, with an average prediction error ranging from 0.01 to 0.03(dimensionless).
conclusionThis study introduces a novel dose prediction model, SegMambaDP, designed to accurately forecast clinical dose distributions for head and neck and cervical cancer patients. SegMambaDP can offer a potential solution for dose distribution prediction in computer-assisted radiotherapy planning systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.